본문 바로가기
KERD
논문KCI 등재

Sublobar Resection Versus Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류의학일반

초록

Purpose Stereotactic body radiotherapy (SBRT) had been increasingly recognized as a favorable alternative to surgical resection in patients with high risk for surgery. This study compared survival outcomes between sublobar resection (SLR) and SBRT for clinical stage I non–small cell lung cancer (NSCLC). Materials and Methods Data were obtained from the Korean Association of Lung Cancer Registry, a sampled nationwide database. This study retrospectively reviewed 382 patients with clinical stage I NSCLC who underwent curative SLR or SBRT from 2014 to 2016. Results Of the patients, 43 and 339 underwent SBRT and SLR, respectively. Patients in the SBRT group were older and had worse pulmonary function. The 3-year overall survival (OS) rate was significantly better in the SLR group compared with the SBRT group (86.6% vs. 57%, log-rank p < 0.001). However, after adjusting for age, sex, tumor size, pulmonary function, histology, smoking history, and adjuvant therapy, treatment modality was not an independent prognostic factor for survival (hazard ratio, 0.99; 95% confidence interval, 0.43 to 2.77; p=0.974). We performed subgroup analysis in the following high-risk populations: patients who were older than 75 years; patients who were older than 70 years and had diffusing capacity of lung for carbon monoxide ≤ 80%. In each subgroup, there were no differences in OS and recurrence-free survival between patients who underwent SLR and those who received SBRT. Conclusion In our study, there were no significant differences in terms of survival or recurrence between SBRT and SLR in medically compromised stage I NSCLC patients. Our findings suggest that SBRT could be considered as a potential treatment option for selected patients.

Abstract

Purpose Stereotactic body radiotherapy (SBRT) had been increasingly recognized as a favorable alternative to surgical resection in patients with high risk for surgery. This study compared survival outcomes between sublobar resection (SLR) and SBRT for clinical stage I non–small cell lung cancer (NSCLC). Materials and Methods Data were obtained from the Korean Association of Lung Cancer Registry, a sampled nationwide database. This study retrospectively reviewed 382 patients with clinical stage I NSCLC who underwent curative SLR or SBRT from 2014 to 2016. Results Of the patients, 43 and 339 underwent SBRT and SLR, respectively. Patients in the SBRT group were older and had worse pulmonary function. The 3-year overall survival (OS) rate was significantly better in the SLR group compared with the SBRT group (86.6% vs. 57%, log-rank p < 0.001). However, after adjusting for age, sex, tumor size, pulmonary function, histology, smoking history, and adjuvant therapy, treatment modality was not an independent prognostic factor for survival (hazard ratio, 0.99; 95% confidence interval, 0.43 to 2.77; p=0.974). We performed subgroup analysis in the following high-risk populations: patients who were older than 75 years; patients who were older than 70 years and had diffusing capacity of lung for carbon monoxide ≤ 80%. In each subgroup, there were no differences in OS and recurrence-free survival between patients who underwent SLR and those who received SBRT. Conclusion In our study, there were no significant differences in terms of survival or recurrence between SBRT and SLR in medically compromised stage I NSCLC patients. Our findings suggest that SBRT could be considered as a potential treatment option for selected patients.

참고문헌 (24)

  1. Senan S, "Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy?", Lancet Oncol, 14, pp.e270~e274 (2013)
  2. Lagerwaard FJ, "Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer", Int J Radiat Oncol Biol Phys, 83, pp.348~353 (2012)
  3. Nagata Y, "Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer : Japan Clinical Oncology Group Study JCOG0403", Int J Radiat Oncol Biol Phys, 93, pp.989~996 (2015)
  4. Timmerman RD, "Stereotactic body radiation therapy for operable early-stage lung cancer : findings from the NRG oncology RTOG 0618 trial", JAMA Oncol, 4, pp.1263~1266 (2018)
  5. Onishi H, "Stereotactic body radiotherapy(SBRT)for operable stage I non-small-cell lung cancer : can SBRT be comparable to surgery?", Int J Radiat Oncol Biol Phys, 81, pp.1352~1358 (2011)
  6. Matsuo Y, "Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy : a propensity score matching analysis", Eur J Cancer, 50, pp.2932~2938 (2014)
  7. Varlotto J, "Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery", Cancer, 119, pp.2683~2691 (2013)
  8. Chang JY, "Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer : a pooled analysis of two randomised trials", Lancet Oncol, 16, pp.630~637 (2015)
  9. Crabtree TD, "Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer", J Thorac Cardiovasc Surg, 140, pp.377~386 (2010)
  10. Paul S, "Long term survival with stereotactic ablative radiotherapy(SABR)versus thoracoscopic sublobar lung resection in elderly people : national population based study with propensity matched comparative analysis", BMJ, 354, pp.i3570~ (2016)
  11. Grills IS, "Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer", J Clin Oncol, 28, pp.928~935 (2010)
  12. Wu J, "Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage non-small cell lung cancer : a National Cancer Database study", J Thorac Cardiovasc Surg, 160, pp.1350~1357 (2020)
  13. Wang HH, "Sublobar resection is associated with improved outcomes over radiotherapy in the management of high-risk elderly patients with stage I non-small cell lung cancer : a systematic review and meta-analysis", Oncotarget, 8, pp.6033~6042 (2017)
  14. Poullis M, "Treatment outcomes in stage I lung cancer : a comparison of surgery and stereotactic body radiation therapy", J Thorac Oncol, 11, pp.e64~5 (2016)
  15. Tandberg DJ, "Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer : a comprehensive review", Cancer, 124, pp.667~678 (2018)
  16. 최창민, "Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014", Cancer Research and Treatment, 51(4), pp.1400~1410 (2019), 대한암학회
  17. 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
  18. Annual report of cancer statistics in Korea in 2016, "Korea Central Cancer Registry, National Cancer Center", Ministry of Health and Welfare, ~ (2016)
  19. Black K, "Business statistics for contemporary decision making" (2004), John Wiley & Sons
  20. Edge SB, "AJCC cancer staging manual" (2010), Springer
  21. Brunelli A, "ERS", ESTS clinical guidelines on fitness for radical therapy in lung cancer patients(surgery and chemo-radiotherapy), 2009, pp.34, 17~41
  22. Moreno AC, "Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC", J Thorac Oncol, 15, pp.101~109 (2020)
  23. Ginsberg RJ, "Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group", Ann Thorac Surg, 60, pp.615~622 (1995)
  24. Port JL, "A propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer", Ann Thorac Surg, 98, pp.1152~1159 (2014)

관련 논문AI추천

Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience김수산, 송시열, 신영섭, 이세원, 장정윤, 지원준, 최은경, 최창민대한암학회 · Cancer Research and Treatment2023 · 제55권 제4호Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea김연실, 김재성, 김진희, 김학재, 문성호, 송상혁, 송시열, 안용찬, 윤선민, 장지현, 조문준대한암학회 · Cancer Research and Treatment2017 · 제49권 제3호Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules노재명, 안용찬, 오동률, 조원경, 표홍렬대한암학회 · Cancer Research and Treatment2016 · 제48권 제4호Association of Shorter Time to Recurrence and Recurrence-free Survival with Transthoracic Lung Biopsy in Stage I Lung Cancer박형인, 윤순호, 채금주, 홍현숙대한암학회 · Cancer Research and Treatment2025 · 제57권 제2호Active Treatment Improves Overall Survival in Extremely Older Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study이수연, 이재철, 지원준, 최창민, 홍윤기, Korea Central Cancer Registry, Korean Association for Lung Cancer대한암학회 · Cancer Research and Treatment2021 · 제53권 제1호The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer:Evidence for Changing ParadigmsMax Dahele, Suresh Senan대한암학회 · Cancer Research and Treatment2011 · 제43권 제2호

이 간행물의 다른 논문 (30건)